TMB-L

Single-cell RNA sequencing illustrated the cellular distribution of model genes, and functional experiments demonstrated that XCL2 suppresses melanoma cell proliferation, migration, and invasion. This study develops and validates a cuproptosis-immune integrated prognostic signature for SKCM, providing a framework to link cuproptosis-associated biology with immune microenvironmental features, risk stratification, and potential therapeutic decision-making.

No disease progression was observed at 9 months. This case demonstrates the potential efficacy of combination immunotherapy in aggressive metastatic MTSCC.

Integrated profiling of TETs reveals distinct genomic, transcriptomic, and immune features across subtypes of TETs and identifies potentially actionable therapeutic targets that may inform future treatment strategies.

Leveraging clinical feasible RNA-seq and TMB analysis, our model exhibits robust predictive efficacy of ICB response in multiple cancers, enabling subtype-tailored therapeutic combinations to improve immunotherapy response.

Here, we provide a brief overview of NETs, including their current diagnosis and management, and present recent progress in understanding the role of epigenetic regulation, highlighting how this may influence NET tumorigenesis and may be used in therapeutic applications. Finally, this literature review emphasizes the need to gather more data on these rare malignancies to improve patient outcome.

Pharmacological inhibitors of EZH2, including tazemetostat, have shown promise in preclinical melanoma models by restoring antigen presentation, enhancing CD8+ T-cell infiltration, and reversing transcriptional programs associated with immune resistance. This review aims to summarize the role of EZH2 in the molecular pathogenesis of ALM, emphasizing its contributions to epigenetic regulation, tumor plasticity, and immune escape, and discusses emerging therapeutic strategies targeting EZH2-mediated pathways to improve outcomes for this aggressive melanoma subtype.

Lack of TIL reactivity in a beta-2-microglobulin (B2M)-ablated canine melanoma sample confirmed that recognition was major histocompatibility complex (MHC) class I-dependent. Together, these data establish the feasibility of generating functional canine TIL products and pave the way for comparative trials to evaluate TIL efficacy and novel strategies to enhance responses in low-TMB malignancies.

TMB may serve as a complementary predictive biomarker for dual immunotherapy. PROSPERO, identifier: CRD420251147483.

At clinically relevant doses, ATRA phenocopies ADAR depletion, enhancing antiviral and interferon responses while increasing tumor immunogenicity. In orthotopic immunocompetent DMG models, ATRA enhances CD8+ T cell infiltration and synergizes with ICB and irradiation to improve survival.

Together, these findings position Pfn1 as a critical mediator of ChRCC progression, linking cytoskeletal remodeling to aggressive tumor behavior. This work highlights Pfn1 as a potential therapeutic target and establishes a framework for cytoskeletal-focused strategies in advanced ChRCC.

This study aimed to evaluate the prognostic significance of TMB in patients with unresectable HCC undergoing TACE combined with immunotherapy (camrelizumab) and anti-angiogenic drugs...Cox regression indicated high TMB as an independent predictor of improved PFS and OS. TMB was a valuable prognostic biomarker for HCC patients undergoing TACE with immunotherapy and anti-angiogenic agents, correlating with enhanced survival and treatment response.

MTAP loss defines a clinically adverse subset across advanced solid tumors, characterized by co-deletion of CDKN2A/B and type I interferon cluster genes, reduced T-cell infiltration, and resistance to ICB. These findings provide a mechanistic context for ICB resistance.